159857-65-5

Upstream product

• 159857-62-2 Fmoc-Phe-Lys(MMT) 
• 159857-61-1 (S)-2-amino-6-((4-methoxyphenyl)diphenylmethyl-amino)hexanoic acid 
• 450366-22-0 Fmoc-Lys(Mmt)-aminobenzyl alcohol 
• 159857-63-3 Fmoc-Phe-Lys(MMT)-PABOH 
• 159857-60-0 Fmoc-Lys(Mmt)-OH 
• 623-04-1 4-aminobenzenemethanol 
• 55750-63-5 6-maleimidohexanoic acid N-hydroxylsuccinimide ester 
• 159857-64-4 (S)-2-((S)-2-amino-3-phenyl-propionylamino)-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide 

Downstream Products

• 159857-66-6 Carbonic acid 4-((S)-2-{(S)-2-[6-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-hexanoylamino]-3-phenyl-propionylamino}-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoylamino)-benzyl ester 4-nitro-phenyl ester 
• 1083198-41-7 C₈₀H₈₃N₇O₁₅ 

Relevant academic research and scientific papers

Synthesis of an immunoconjugate of camptothecin

The first immunoconjugate of camptothecin has been synthesized wherein the drug is attached to the tumor-recognizing antibody BR96 via a Cathepsin B cleavable linker. Endocytosis of the immunoconjugate upon binding to the tumor cell followed by enzymatic cleavage of the linker inside the endosome ensures tumor-specific release of the drug. In this way, it is hoped that the dose-limiting side effects associated with camptothecin can be eliminated while the antitumor activity is preserved.

Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles

Cathepsin B-sensitive maleimidocaproyl-Phe-Lys linker compounds containing acid-sensitive anticancer drugs doxorubicin, mitomycin C and paclitaxel (taxol) attached through a self-immolative p-aminobenzylcarbonyl spacer were prepared using monomethoxytrityl (MMT) as the amino protecting group for Lys. MMT could be removed cleanly and in high yield by dichloroacetic and chloroacetic acids in the presence of anisole with minimal workup.